Evotec SE
EVOTEC AND FERRING FORM STRATEGIC RESEARCH ALLIANCE IN REPRODUCTIVE MEDICINE AND WOMEN’S HEALTH
DGAP-News: Evotec AG / Key word(s): Miscellaneous EVOTEC AND FERRING FORM STRATEGIC RESEARCH ALLIANCE IN REPRODUCTIVE MEDICINE AND WOMEN’S HEALTH – FERRING ACCESSES EVOTEC’S INTEGRATED SMALL MOLECULE DISCOVERY AND DEVELOPMENT PLATFORM TO PROGRESS NEW MOLECULES FROM CONCEPT TO POTENTIAL DRUG CANDIDATES – EVOTEC IS ELIGIBLE FOR UNDISCLOSED RESEARCH FUNDING AND MILESTONES
Hamburg, Germany; Saint-Prex, Switzerland, 17 October 2018: Evotec will apply its drug discovery platform to design novel, safe and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (“PDC”) and investigational new drug (“IND”) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones. Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The integration of our industry-leading small molecule discovery and development platform with Ferring’s deep disease expertise in reproductive medicine and women’s health will create a powerful combination that we hope will create a difference for patients suffering from infertility and gynaecological disorders. We very much look forward to working with such an innovative partner.” Per Falk, Chief Science Officer, Ferring, added: “To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics. Evotec is a highly regarded company in this field, and this alliance offers the prospect of significant innovation for patients. Together, we have the potential to make a difference for both men and women who are struggling to start a family, and for women suffering from gynaecological conditions.”
Learn more at WWW.FERRING.COM, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube. FOR MORE INFORMATION, PLEASE CONTACT Bhavin Vaid Lindsey Rodger
Contact Evotec AG: Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com
17.10.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Evotec AG |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | info@evotec.com |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |
Aktuelle News
Aktuelle Berichte
Anstehende Events
Events Funktionen
Weitere Funktionen
Webcasts
Events Funktionen
Weitere Funktionen
10
Mai 23
Evotec SE
Conference Call on the new partnership between Just – Evotec Biologics and Sandoz